CMS, INC., AN ELEKTA COMPANY, ANNOUNCES FIRST CANCER PATIENTS TREATED WITH MONACO™ RADIATION TREATMENT PLANNING SYSTEM

CMS, INC., AN ELEKTA COMPANY, ANNOUNCES FIRST CANCER PATIENTS TREATED WITH
MONACO™ RADIATION TREATMENT PLANNING SYSTEM

Press Release 
St Louis, Missouri, USA, August 29, 2008

CMS, Inc., an Elekta Company and worldwide leader in radiation treatment
planning and workflow management solutions, announced that three sites have
delivered clinical treatments utilizing Monaco™, its next-generation Intensity
Modulated Radiotherapy (IMRT) treatment planning system. Allegheny General
Hospital in Pittsburgh, Pennsylvania, Erasmus Medical Center in Rotterdam,
Netherlands, and Froedtert Memorial Lutheran Hospital in Milwaukee, Wisconsin,
have all begun producing treatment plans with the application.


Featuring biological modeling, constrained optimization, and Monte Carlo dose
calculation algorithms, Monaco represents a fundamentally new approach to IMRT
planning, including a unique and sophisticated set of tools to make the
radiotherapy planning process easier, more straightforward and clinically
reliable."The biologically-based Monaco IMRT treatment planning system produces
clinically relevant plans, which are dosimetrically superior to plans from
dose-based IMRT treatment planning systems, feature shorter plan delivery times,
and can be easily verified with normal QA procedures,” says Moyed Miften, Ph.D.,
DABR, and Allegheny General Hospital's Chief of Medical Physics. “The
multi-criteria optimization and the sensitivity analysis tools in the Monaco
system also help reduce the time needed to optimize IMRT plans."

While IMRT delivers significant improvements for radiation treatment, the
technology presents challenges, including managing the time and resource
intensive processes associated with planning. With Monaco, CMS offers new
approaches that improve IMRT planning in the following ways:

Sensitivity Analysis tool that minimizes trial-and-error by guiding the decision
making process Smart Sequencing™, a constrained aperture optimization that
produces efficient step-and-shoot segments Biological models, voxel definition
controls, and multi-criterial goals that provide more intuitive and direct
control over the optimization process.

Monaco was developed with the University of Tűbingen in Germany. Markus Alber,
Ph.D., and colleagues developed the Hyperion project, which is the engine behind
the new Monaco system. CMS commercialized these innovative concepts and
approaches from the Hyperion project to create the foundation for Monaco. The
result is an advanced, clinically sophisticated IMRT planning system backed by
the core research and capabilities of one of the world's leading research
institutions.

About CMS
CMS, Inc., an Elekta Company, is a worldwide market leader in radiation
treatment planning and workflow management, combining innovative software
applications and advanced technology tools to deliver comprehensive treatment
planning and workflow management solutions that integrate seamlessly in any
clinical environment. With a commitment to product excellence and a reputation
for world-class service and support, CMS makes all members of the treatment team
more effective in providing patient care.


For further information, please contact:

David Murphy, CMS, Inc., an Elekta Company.
Tel: +1 314 812 43 20, +1 314 712 0181, e-mail: david.murphy@cmsrtp.com

Lena Schattauer, Investor Relations.
Tel: +46 8 587 25 722, +46 70 595 51 00, e-mail: lena.schattauer@elekta.com  


About Elekta

Elekta is an international medical technology group, providing oncologists,
radiation therapists, neurosurgeons and many other medical specialists with
state of the art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and
information systems as well as services for improved cancer care and management
of brain disorders. 

Elekta's systems and solutions are used in over 5,000 hospitals around the
world. Clinical and information management solutions include, among others,
Leksell Gamma Knife® for non-invasive treatment of brain disorders, Elekta
Axesse™ and Elekta Synergy® for stereotactic and image guided radiation therapy
and radiosurgery as well as the MOSAIQ™ suite of software for image-enabled EMR
and efficient management of clinical and patient data.

With around 2,500 employees globally, the corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Nordic Exchange under the
ticker EKTAb. More information about Elekta can be found at www.elekta.com.